Abstract
Canakinumab (Ilaris®), an anti-interleukin-1β monoclonal antibody, is a novel approach to treat acute gouty arthritis flares in a targeted population of patients in whom treatment options are limited. Relative to on-demand treatment with intramuscular triamcinolone acetonide 40 mg, on-demand treatment with subcutaneous canakinumab 150 mg significantly relieved the pain and inflammation of a new gout flare, and reduced the risk of new flares in patients with acute gouty arthritis flares in whom standard treatment with non-steroidal anti-inflammatories and/or colchicine was inappropriate. Canakinumab has an acceptable tolerability profile in this difficult-to-treat population. The increased risk of infections and neutropenia associated with canakinumab treatment can be minimized by following the recommended precautions.
MeSH terms
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacology
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / genetics
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Arthritis, Gouty / drug therapy*
-
Arthritis, Gouty / immunology
-
Arthritis, Gouty / metabolism
-
Arthritis, Gouty / physiopathology
-
Drug Resistance
-
Humans
-
Interleukin-1beta / antagonists & inhibitors*
-
Interleukin-1beta / metabolism
-
Neutropenia / chemically induced
-
Neutropenia / prevention & control
-
Opportunistic Infections / immunology
-
Opportunistic Infections / prevention & control
-
Practice Guidelines as Topic
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / pharmacology
-
Recombinant Proteins / therapeutic use
-
Severity of Illness Index
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
IL1B protein, human
-
Interleukin-1beta
-
Recombinant Proteins
-
canakinumab